Skip to main content

Comprehensive Care for Persons with Diabetes Faculty And Disclosures.

Statement of Independence
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

This program is sponsored by ACOFP for educational purposes only. The material presented is not intended to represent the sole or best medical interventions for the discussed diagnoses, but rather is intended to present the opinions of the authors or presenters that may be helpful to other practitioners. Attendees participating in this medical education program do so with the full knowledge that they waive any claim they may have against ACOFP for reliance on any information presented during these educational activities.

The American College of Osteopathic Family Physicians (ACOFP) online education is an educational resource and as such does not define a standard of care, nor is it intended to dictate an exclusive course of treatment or procedure to be followed. It presents methods and techniques of clinical practice that are acceptable and used by recognized authorities, for consideration by licensed physicians and healthcare providers to incorporate into their practice. Variations of practice, taking into account the needs of the individual patient, resources, and limitation unique to the institution or type of practice, may be appropriate.

The statements and opinions expressed within this educational program are those of the faculty and not necessarily those of the ACOFP. The ACOFP disclaims any responsibility and/or liability for such information.

Faculty Disclosure Policies
It is the policy of the American College of Osteopathic Family Physicians (ACOFP) to ensure balance, independence, objectivity, and scientific rigor in all its individually sponsored or jointly sponsored educational programs. All faculty participating in any ACOFP sponsored programs are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It remains for the audience to determine whether the speaker's outside interests may reflect a possible bias in either the exposition or the conclusions presented.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The following faculty reported relevant financial relationships: Kevin T. Miller, DO: Advisory Board - Astra Zeneca; Research Funding - Abbott, Pendulum. Elizabeth M. Venditti, PhD: Advisory Board - PeopleOne Health. Jay H. Shubrook, DO, FAAFP, FACOFP: Advisory Board - Novo Nordisk, Bayer, Eli Lilly. John L. Leahy, MD: Advisory Board - Merck & Co, Hillbloom Foundation. Lawrence Blonde, MD, FACP, MACE: Consultant - Corcept Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Lyndra Therapeutics, Merck, Novo Nordisk, Salix Pharmaceuticals, Sanofi. Eden M. Miller, DO: Advisory Board - Abbott, Lilly, Novo Nordisk, Boehringer Ingelheim, Merck, Bayer, Pendulum. Anne L. Peters, MD: Advisory Board - Abbott, Astra Zeneca, Lilly, Medscape, Novo Nodisk, Zealand, Vertex. Leonard R. Bertheau, DO: Speaker - Medtronic. Davida F. Kruger, MSN, APN-BC, BC-ADM: Speaker - Novo Nordisk, Eli Lilly, Abbott, Dexcom, Xeris, Astra Zeneca, Sanofi; Advisor - Novo Nordisk, Eli Lilly, Abbott, Sanofi; Stock Options - Pendulum; Research Funding - Novo Nordisk, Dexcom, Abbott. Mark E. Molitch, MD: Research Funding - Bayer, Novartis; Consultant - Janssen, Merck, Pfizer.

The following faculty reported no relevant financial relationships: Kim Pfotenhauer, DO; Robert S. Gotfried, DO, FAAFP

The American College of Osteopathic Family Physicians (ACOFP) and the Endocrine Society staff associated with the development of this CME activity reported no relevant financial relationships.

The American College of Osteopathic Family Physicians (ACOFP) and the Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.

This activity is not supported by educational grant(s) or other funds from any commercial supporter.


Kim Pfotenhauer, DO
Michigan State University College of Osteopathic Medicine
East Lansing, MI
No disclosures

Kevin T. Miller, DO
Diabetes and Obesity Care
Bend, OR
  • Advisory Board; Astra Zeneca
  • Research Funding: Abbott; Pendulum

Elizabeth M. Venditti, PhD
University of Pittsburgh School of Medicine
Pittsburgh, PA
  • Advisory Board: PeopleOne Health

Jay H. Shubrook, DO, FAAFP, FACOFP
Touro University
Vallejo, CA
  • Advisory Board: Novo Nordisk; Bayer; Eli Lilly

John L. Leahy, MD
University of Vermont
Burlington, VT
  • Advisory Board: Merck & Co.; Hillbloom Foundationtest


Lawrence Blonde, MD, FACP, MACE
Ochsner Medical Center
New Orleans, LA
  • Consultant: Corcept Therapeutics; 
  • Gilead Sciences, Inc.; 
  • Janssen Pharmaceuticals, Inc; 
  • Lyndra Therapeutics; Merck; Novo Nordisk; 
  • Salix Pharmaceuticals; Sanofi

Eden M. Miller, DO
Diabetes and Obesity Care
Bend, OR
  • Advisory Board: Abbott; Lilly USA; Novo Nordisk; Boehringer Ingelheim; Merck; Bayer; Pendulum

Anne L. Peters, MD
University of Southern California
Los Angeles, CA
  • Advisory Board: Abbott Diabetes Care; Astra Zeneca; Lilly; Medscape; Novo Nordisk; Zealand; Vertex

Leonard R. Bertheau, DO
Adventist Health
Portland, OR
  • Speaker: Medtronic

Davida F. Kruger, MSN, APN-BC,BC-ADM
Henry Ford Health System
Detroit, MI
  • Speaker: Novo-Nordisk; Eli Lilly; Abbott Diabetes; Dexcom; Xeris; AstraZeneca; Sanofi
  • Advisor: Novo-Nordisk; Eli Lilly; Abbott Diabetes; Sanofi
  • Stock Options: Pendulum
  • Research Funding: Novo Nordisk; Dexcom; Abbott Diabetes

Robert S. Gotfried, DO, FAAFP
Ohio State University Wexner Medical Center
Columbus, OH
No disclosures

Mark E. Molitch, MD
Northwestern University Feinberg School of Medicine
Chicago, IL
  • Research Funding: Bayer; Novartis
  • Consultant: Janssen; Merck; Pfizer

Go back to Comprehensive Care For Persons With Diabetes: A Certificate Program